Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting loss of heterozygosity for cancer-specific immunotherapy
Michael S. Hwang, Brian J. Mog, Jacqueline Douglass, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 12
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute, et al.
Nature Reviews Clinical Oncology (2022) Vol. 20, Iss. 1, pp. 49-62
Open Access | Times Cited: 237
Targeting public neoantigens for cancer immunotherapy
Alexander H. Pearlman, Michael S. Hwang, Maximilian F. Konig, et al.
Nature Cancer (2021) Vol. 2, Iss. 5, pp. 487-497
Open Access | Times Cited: 129
Effects of aneuploidy on cell behaviour and function
Rong Li, Jin Zhu
Nature Reviews Molecular Cell Biology (2022) Vol. 23, Iss. 4, pp. 250-265
Closed Access | Times Cited: 101
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Mohamad Hamieh, Jorge Mansilla‐Soto, Isabelle Rivière, et al.
Cancer Discovery (2023) Vol. 13, Iss. 4, pp. 829-843
Open Access | Times Cited: 64
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Yaxian Kong, Jingyao Li, Xia Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 2
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
Talar Tokatlian, Grace E. Asuelime, Jee‐Young Mock, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003826-e003826
Open Access | Times Cited: 46
A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo
Mark L. Sandberg, Xueyin Wang, Aaron D. Martin, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 634
Closed Access | Times Cited: 41
CAR T cells: Building on the CD19 paradigm
Anat Globerson Levin, Isabelle Rivière, Zelig Eshhar, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 9, pp. 2151-2163
Open Access | Times Cited: 54
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes
Natalia Aptsiauri, Federico Garrido
Clinical Cancer Research (2022) Vol. 28, Iss. 23, pp. 5021-5029
Open Access | Times Cited: 33
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
Piotr Celichowski, Marcello Turi, Sandra Charvátová, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 21
Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens
Anup Y. Parikh, Robert J. Masi, Billel Gasmi, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 10, pp. 3149-3162
Open Access | Times Cited: 21
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
Nathanael J. Bangayan, Liang Wang, Giselle Burton Sojo, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 47
Open Access | Times Cited: 17
Implementing Logic Gates for Safer Immunotherapy of Cancer
Mohammed Azharuddin Savanur, Hadas Weinstein-Marom, Gideon Gross
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 33
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers
Wan Ching Lim, Maria Eugénia Marques Da Costa, Karine Godefroy, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 5
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
Ashley L. Cook, Surojit Sur, Laura Dobbyn, et al.
eLife (2025) Vol. 13
Open Access
Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy
Breanna DiAndreth, Pavlo A. Nesterenko, Aaron Winters, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
Brian J. Mog, Nikita Marcou, Sarah R. DiNapoli, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 755
Closed Access | Times Cited: 4
Analysis of biopsies of gastric cancer, intestinal and diffuse, and non-atrophic gastritis: an overview of loss of heterozygosity in Mexican patients
Violeta Larios‐Serrato, Hilda-Alicia Valdez‐Salazar, Javier Torres, et al.
PeerJ (2025) Vol. 13, pp. e18928-e18928
Open Access
Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines
Saranya Pounraj, Shuxiong Chen, Linlin Ma, et al.
Cancer Research (2023) Vol. 84, Iss. 3, pp. 353-363
Closed Access | Times Cited: 10
Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology
Ralf Huss, Johannes Raffler, Bruno Märkl
Cancer Reports (2023) Vol. 6, Iss. 7
Open Access | Times Cited: 9
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
Ariane Lozac’hmeur, Tyler Danek, Qidi Yang, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
The Tmod cellular logic gate as a solution for tumor-selective immunotherapy
Breanna DiAndreth, Agnes E. Hamburger, Xu Han, et al.
Clinical Immunology (2022) Vol. 241, pp. 109030-109030
Open Access | Times Cited: 15
Recent progress of gene circuit designs in immune cell therapies
Seung‐Hee Lee, Ahmad S. Khalil, Wilson W. Wong
Cell Systems (2022) Vol. 13, Iss. 11, pp. 864-873
Open Access | Times Cited: 14
Building safety into CAR-T therapy
D. Peters, Barbara Savoldo, Natalie S. Grover
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 3
Open Access | Times Cited: 8
Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor
Fan Fei, Rong Liang, Nan Jiang, et al.
Molecular Therapy (2021) Vol. 30, Iss. 3, pp. 1215-1226
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top